[Skip to content]

Print this page
.

NICE Technology Appraisals

This is a list of the published NICE technology appraisals. Technology appraisals are recommendations on the use of new and existing medicines and treatments within the NHS.

NICE TAs: 1-20;  21-40;  41-60 61-8081-100101-120121-140141-160;  161-180181-200201-220221-240241-260261-280; 281+

NICE TAs 161-180

 

REF

 

TITLE

 

DHFT Formulary link

East Midlands Cancer Network link (cancer drugs only)

TA161

Osteoporosis - secondary prevention including strontium ranelate (TA161)  

6.6 Drugs affecting bone metabolism: 6.6.1 Calcitonin and parathyroid hormone & 6.6.2 Bisphosphonates and other drugs affecting bone metabolism.

 

TA162

Lung cancer (non-small-cell) - erlotinib (TA162)

 

EMCN algorithm

DHFT protocol

TA163

Ulcerative colitis (acute exacerbations) - infliximab (TA163)

1.5 Treatment of chronic diarrhoeas: 1.5.3 Drugs affecting the immune response

 

TA164

Hyperuricaemia - febuxostat (TA164)  

10.1.2 - 10.1.4 Corticosteroids, rheumatic disease suppressants, gout: 10.1.4 Drugs for treatment of gout

 

TA165 

Organ preservation (renal) - machine perfusion and static storage (TA165)

No drug implications

 

TA166

Hearing impairment - cochlear implants (TA166)  

No drug implications

 

TA167 

Abdominal aortic aneurysm - endovascular stent-grafts (TA167)

No drug implications

 

TA168

Influenza - zanamivir, amantadine and oseltamivir (review) (TA168)

5.3 Antiviral drugs: 5.3.4 Influenza

 

TA169

Renal cell carcinoma - sunitinib (TA169)

 

EMCN algorithm

DHFT protocol 

TA170

Venous thromboembolism - rivaroxaban (TA170)

2.8 Anticoagulants: 2.8.2 Oral anticoagulants

 

TA171

Multiple myeloma - lenalidomide (TA171)

8.2 Drugs affecting the immune response: 8.2.4 Other Immunomodulating Drugs

EMCN algorithm

DHFT protocol 

TA172

Head and neck cancer (squamous cell carcinoma) - cetuximab (TA172)

 

EMCN algorithm

DHFT protocol

TA173

Hepatitis B - tenofovir disoproxil fumarate (TA173)

5.3 Antiviral drugs: 5.3.1 HIV Infection

 

TA174

Leukaemia (chronic lymphocytic, first line) - rituximab (TA174)

8.2 Drugs affecting the immune response: 8.2.2 Rituximab & Alemtuzumab

EMCN algorithm

DHFT protocol 

TA175

Lung cancer (non-small-cell, second line) - gefitinib (terminated appraisal) (TA175)

Withdrawn

 

TA176

Colorectal cancer (first line) - cetuximab (TA176)

 

EMCN algorithm

DHFT protocol

TA177

Eczema (chronic) - alitretinoin (TA177)

13.5.1 Preparations for eczema & psoriasis

 

TA178

Renal cell carcinoma (TA178)

 

EMCN algorithm

DHFT protocol

TA179

Gastrointestinal stromal tumours - sunitinib (TA179)

 

EMCN algorithm

DHFT protocol

TA180

Psoriasis - ustekinumab (TA180)

13.5.3 Drugs affecting the immune response